Efficacy and Safety of Ablative Therapy in the Treatment of Patients with Metastatic Pheochromocytoma and Paraganglioma.
cryoablation
minimally invasive procedure
neuroendocrine tumor
percutaneous ablation
percutaneous ethanol injection
radiofrequency ablation
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
07 Feb 2019
07 Feb 2019
Historique:
received:
12
01
2019
revised:
03
02
2019
accepted:
05
02
2019
entrez:
10
2
2019
pubmed:
10
2
2019
medline:
10
2
2019
Statut:
epublish
Résumé
Metastatic pheochromocytoma and paraganglioma (PPGL) are incurable neuroendocrine tumors. The goals of treatment include palliating symptoms and reducing tumor burden. Little is known about the use of radiofrequency ablation (RFA), cryoablation (CRYO), and percutaneous ethanol injection (PEI) to treat metastatic PPGL. We performed a retrospective study of patients age 17 years and older with metastatic PPGL who were treated with ablative therapy at Mayo Clinic, USA, between June 14, 1999 and November 14, 2017. Our outcomes measures were radiographic response, procedure-related complications, and symptomatic improvement. Thirty-one patients with metastatic PPGL had 123 lesions treated during 42 RFA, 23 CRYO, and 4 PEI procedures. The median duration of follow-up was 60 months (range, 0⁻163 months) for non-deceased patients. Radiographic local control was achieved in 69/80 (86%) lesions. Improvement in metastasis-related pain or symptoms of catecholamine excess was achieved in 12/13 (92%) procedures. Thirty-three (67%) procedures had no known complications. Clavien-Dindo Grade I, II, IV, and V complications occurred after 7 (14%), 7 (14%), 1 (2%), and 1 (2%) of the procedures, respectively. In patients with metastatic PPGL, ablative therapy can effectively achieve local control and palliate symptoms.
Identifiants
pubmed: 30736463
pii: cancers11020195
doi: 10.3390/cancers11020195
pmc: PMC6407137
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Ann Surg. 1999 Jun;229(6):755-64; discussion 764-6
pubmed: 10363888
J Natl Cancer Inst. 2001 Apr 18;93(8):648-9
pubmed: 11309443
Ann Surg. 2004 Aug;240(2):205-13
pubmed: 15273542
Kidney Int. 1991 Sep;40(3):544-56
pubmed: 1787652
J Vasc Interv Radiol. 2009 May;20(5):670-3
pubmed: 19328724
J Vasc Interv Radiol. 2009 Nov;20(11):1483-90
pubmed: 19875067
Pancreas. 2010 Aug;39(6):775-83
pubmed: 20664475
J Vasc Interv Radiol. 2011 Sep;22(9):1263-70
pubmed: 21856504
J Vasc Interv Radiol. 2012 Jan;23(1):48-54
pubmed: 22037491
J Vasc Interv Radiol. 2014 Apr;25(4):593-8
pubmed: 24507995
J Urol. 2014 Aug;192(2):357-63
pubmed: 24631107
J Clin Endocrinol Metab. 2017 Sep 1;102(9):3296-3305
pubmed: 28605453
Clin Endocrinol (Oxf). 2017 Nov;87(5):440-450
pubmed: 28746746
Endocrine. 2018 Mar;59(3):547-554
pubmed: 29305799
AJNR Am J Neuroradiol. 1994 Feb;15(2):357-63
pubmed: 8192086
Hypertension. 1997 May;29(5):1133-9
pubmed: 9149678